Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy: Due for a correction? - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jun 21, 2000

    Ranbaxy: Due for a correction?

    There have been rumours about the imminent receipt of a milestone payment by Ranbaxy from Bayer, which seems to have propelled a movement in Ranbaxy’s stock price. Over the last one month (i.e. from May 22nd till June 20th 2000), the stock has jumped almost 33%.

    Around the same time, Dr. Brian Tempest, President, Pharmaceuticals is reported to have indicated a figure of $ 500 m (approximately Rs 22.54 bn) of annual turnover for the current year ending December 2000. We beg to differ.

    First, the company derives almost half of its turnover from India and the Middle East of which the Indian market accounts for 90% of the regional revenue. The Indian market has been witnessing a sharp slowdown over the last two years with overall growth of not more than 10% per annum. The antibiotic/antibacterial segment in which the company has a major presence (these account for almost 53% of the company’s domestic turnover) has been particularly slack.

    Therapeutic Area Domestic % of Sales Exports % of Sales
    Anti–Infectives 3,655.1 53.0% 1,755.1 57.8%
    Gastro Intestinal tract 526.3 7.6% 378.1 12.5%
    Nutritional/Multivitamins 554.6 8.0% 296.3 9.8%
    Analgesics/NSAIDs 493.9 7.2% 163.0 5.4%
    Dermatiologicals 541.0 7.8% 4.8 0.2%
    Cardiovascular 292.0 4.2% 46.0 1.5%
    Orthopaedics 293.9 4.3% 0.7 0.0%
    CNS 223.4 3.2% 11.1 0.4%
    Others 313.9 4.6% 379.2 12.5%
    TOTAL 6,894.1 100.0% 3,034.3 100%

    Second, even if one were to check out the domestic divisional performance, the pharma division’s (which targets general practioners) performance has been reflective of the slowdown. What is likely to lead to topline growth is the performance of Stancare and Solus, which deal with therapeutic areas such as cardiovascular and central nervous system.

    Divisions CY99 CY2000E Growth (E)
    Pharma 4,123.5 4,504.9 9.3%
    Stancare 1,174.0 1,420.5 21.0%
    Solus 356.3 481.0 35.0%
    Rexcel 857.1 900.0 5.0%
    Croslands 937.0 1,056.0 12.7%
    TOTAL 7,447.9 8,362.4  
    API 423.5 508.2 20.0%
    Grand Total 7,871.4 8,870.6  

    • Pharma: This division deals with the old and famous brands of the company. Targets general practitioners
    • Stancare: Deals with specialised drugs and targets specialists
    • Solus: Deals in cardiovascular and central nervous system drugs
    • Rexcel: Deals with brands such acquired from Gufic for instance Mox
    • Croslands: Deals in drugs related to dermatology (skin infections) and orthopaedics

    Thirdly, even in the first quarter of the current year Ranbaxy has reported a topline growth of hardly 3.2% (the bottomline has declined 19.4%). With almost over 50% of the company’s revenue accruing from products under the Drug Price Control Order (DPCO) it is difficult to visualise a 35% growth in the current year’s topline. Overall we expect the company to report a turnover in the range of Rs 17.85 bn for the year ending December 2000.

    Perhaps, the only trump card in Ranbaxy’s armoury is the sale of RBx 2258 (the benign prostrate hyperplasia molecule) which is expected to be launched in the current year. If that does not happen, the scrip is unlikely to continue its outperformance for long.



    Equitymaster requests your view! Post a comment on "Ranbaxy: Due for a correction?". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Apr 1, 2015 (Close)


    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks